Colorectal cancer
Conditions
Interventions
experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g
Sponsors
The Second Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, male or female; 2. Patients with pathologically or histologically confirmed colorectal cancer; 3. High-risk stage II patients; 4. Patients with stage III; 5. Four weeks after surgery; 6. ECOG 0-2; 7. Adequate hematologic function: neutrophil absolute count >= 1.5 x 10^9/L, platelet count >= 100 x 10^9/L, hemoglobin >= 90 g/L; 8. Adequate liver function: Aspartate transferase (AST) = 50 ml/min (Cockcroft-Gault formula); 10. Adequate coagulation function: International standardized ratio (INR) or prothrombin time (PT) <= 1.5 times normal upper limit; If the patient is receiving anticoagulant therapy, INR/PT is within the prescribed anticoagulant range; 11. The subject understands and voluntarily signs the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Received molecular targeted drug therapy, radiotherapy and chemotherapy other than apatinib before enrollment; 3. Patients with grade II or higher myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (including QTc interval >= 450 ms in males and >= 470 ms i n females); 4. Patients with active bleeding; 5. Patients with gastrointestinal ulcer, intestinal perforation or intestinal obstruction; 6. Hypertension patients with poor blood pressure control after antihypertensive drug treatment (systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg); 7. Urine routine showed urine protein >= ++ or confirmed 24-hour urine protein quantification > 1.0 g; 8. Have a history of mental illness or substance abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactZhou Lianbang
The Second Affiliated Hospital of Anhui Medical University
Outcome results
None listed